Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease

Journal of Crohn's and Colitis

Volumn 8, Issue 5, 2014, Pages 375-383

  Choi, Grace K H ^a   Collins, Stephanie D E ^a   Greer, Daniel P ^a   Warren, Lisa ^a   Dowson, Grace ^a   Clark, Tanya ^a   Hamlin, P John ^a   Ford, Alexander C ^a,b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Adalimumab; Crohn's disease; Infliximab

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; COLESTYRAMINE; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; BIOLOGICAL THERAPY; BODY WEIGHT; CHILD; CONFIDENCE INTERVAL; CROHN DISEASE; DEPRESSION; DISEASE DURATION; DISEASE EXACERBATION; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ALGORITHM; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS;

ADOLESCENT; ADULT; ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; COST-BENEFIT ANALYSIS; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; REMISSION INDUCTION;

EID: 84897440381     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.09.017     Document Type: Article

References (32)

1. Kappelman M.D., Rifas-Shiman S.L., Kleinman K., Ollendorf D., Bousvaros A., Grand R.J. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007, 5:1424-1429.
2. Loftus C.G., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Tremaine W.J., Melton L.J., et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007, 13:254-261.
3. Loftus E.V., Silverstein M.D., Sandborn W.J., Tremaine W.J., Harmsen W.S., Zinsmeister A.R. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1999, 116:1161-1168.
4. Candy S., Wright J., Gerber M., Adams G., Gerig M., Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678.
5. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995, 332:292-297.
6. Feagan B.G., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000, 342:1627-1632.
7. Khan K.J., Dubinsky M.C., Ford A.C., Ullman T.A., Talley N.J., Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:630-642.
8. Suares N.C., Hamlin P.J., Greer D.P., Warren L., Clark T., Ford A.C. Efficacy and tolerability of methotrexate therapy for refractory Crohn's disease: a large single-centre experience. Aliment Pharmacol Ther 2012, 35:284-291.
9. Summers R.W., Switz D.M., Sessions J.T., Becktel J.M., Best W.R., Kern F., et al. National cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1979, 77:847-869.
10. Colombel J.-F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
11. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.-F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
12. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumour necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
13. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
14. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.-F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
15. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
16. Targan S.R., Hanauer S.B., van Deventer S.J.H., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor α for Crohn's disease. N Engl J Med 1997, 337:1029-1035.
17. Colombel J.-F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
18. Ford A.C., Sandborn W.J., Khan K.J., Hanauer S.B., Talley N.J., Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:644-659.
19. Mayberry J.F., Lobo A., Ford A.C., Thomas A. NICE clinical guideline (CG152): the management of Crohn's disease in adults, children and young people. Aliment Pharmacol Ther 2013, 37:195-203.
20. TA187 Crohn's disease - infliximab (review) and adalimumab (review of TA40): guidance [Accessed 20th July 2013]. http://www.nice.org.uk/nicemedia/live/12985/48552/48552pdf.
21. Osterman M.T., Haynes K., Delzell E., Zhang J., Bewtra M., Brensinger C., et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol 2013, 10.1016/j.cgh.2013.06.010.
22. Kestens C., van Oijen M.G., Mulder C.L., van Bodegraven A.A., Dijkstra G., de Jong D., et al. Dutch Initiative on Crohn's and Colitis (ICC). Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents. Clin Gastroenterol Hepatol 2013, 11:826-831.
23. Sussman D.A., Kubiliun N., Mulani P.M., Chao J., Yang M., Lu M., et al. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis 2012, 18:2043-2055.
24. Sprakes M.B., Ford A.C., Warren L., Greer D., Hamlin J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis 2012, 6:143-153.
25. Sprakes M.B., Ford A.C., Suares N.C., Warren L., Greer D., Donnellan C.F., et al. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience. Aliment Pharmacol Ther 2010, 32:1357-1363.
26. Sprakes M.B., Hamlin P.J., Warren L., Greer D., Ford A.C. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: a single centre experience. J Crohns Colitis 2011, 5:324-331.
27. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl. A):5-36.
28. NHS reference costs 2010-11 [Accessed 20th July 2013]. http://data.gov.uk/dataset/nhs-reference-costs-2010-11.
29. British National Formulary [Accessed 20th July 2013]. http://www.bnf.org/bnf/index.htm.
30. Bultman E., de Haar C., van Liere-Baron A., Verhoog H., West R.L., Kuipers E.J., et al. Predictors of dose escalation of adalimumab in a prospective cohort of Crohn's disease patients. Aliment Pharmacol Ther 2012, 35:335-341.
31. Gecse K.B., Khanna R., van den Brink G.R., Ponsioen C., Lowenberg M., Jairath V., et al. Biosimilars in IBD: hope or expectation?. Gut 2013, 62:803-807.
32. Danese S., Gomollon F., Governing Board Operational Board of ECCO ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013, 7:586-589.